Executive Summary
The preclinical evaluation of in vivo Chimeric Antigen Receptor (CAR)-T cell therapies requires a departure from established ex vivo protocols. The strategy must account for the biodistribution of the vector, the efficiency of in body cell transduction, and the potential for unique immunogenic responses. A tailored preclinical program focuses on selecting relevant animal models to demonstrate proof-of-concept, defining the safety profile regarding cytokine release syndrome (CRS) and neurotoxicity, and generating a robust data package suitable for Investigational Medicinal Product Dossier (IMPD) submissions to agencies like the MHRA.
Frequently Asked Questions
Q: What are the primary challenges in designing IND-enabling toxicology studies for in-vivo CAR-T therapies?
The main challenges involve the simultaneous evaluation of the delivery vector (e.g., Lentivirus or LNP) and the resulting engineered T-cell population within a single system. This requires complex animal models that can recapitulate human hematopoiesis and tumor microenvironments, alongside a bioanalytical strategy to measure both vector clearance and CAR-T cell persistence and function.
Q: How are animal models selected for assessing therapies targeting hematological malignancies?
Model selection is dictated by the therapy’s mechanism of action and target. For hematological cancers, immunodeficient models engrafted with human CD34+ hematopoietic stem cells and a human tumor cell line are often used. This allows for the evaluation of anti-tumor efficacy against a human target and persistence of the human CAR-T cells generated in vivo.
Q: What bioanalytical support is needed for an Advanced Therapy Medicinal Product (ATMP) submission in the UK?
A comprehensive bioanalytical package for an ATMP submission to the MHRA requires phase-appropriate validated assays. Key assays include quantitative methods (qPCR/ddPCR) to determine vector and CAR transgene levels in blood and tissues (non-target tissue biodistribution), flow cytometry to phenotype and quantify CAR-T cells, and ligand-binding assays to assess host immune responses to the vector and CAR construct.
A standard preclinical template does not exist for *in vivo* CAR-T cell programs. These next-generation therapies, which perform genetic engineering directly within the patient, combine the challenges of vector-based delivery with the complexities of a living cellular therapeutic. Designing an appropriate preclinical strategy is fundamental to minimizing clinical risk and achieving regulatory alignment.
The core objective is to generate definitive data on pharmacodynamics, pharmacokinetics, and toxicology. This is accomplished through meticulously designed studies in highly relevant animal models. For programs targeting hematological malignancies, this often involves using immunodeficient models reconstituted with a human immune system component to properly assess efficacy and persistence.
Immunogenicity and Safety Profile
Assessing the host immune response is a primary objective. While much of the literature focuses on AAV vectors, the strategic principles for evaluating immunogenicity are broadly applicable. A comprehensive assessment of humoral, innate, and T-cell immune responses to the delivery vector is required to understand potential impacts on safety and efficacy (PMID: 29668327). This multi-faceted approach provides a clearer picture of the potential for vector neutralization or other immune-mediated toxicities.
Key safety endpoints for any CAR-T program include monitoring for:
-
Cytokine Release Syndrome (CRS): Assessed through multiplex analysis of key human cytokines (e.g., IL-6, IFN-γ) in plasma samples from study animals.
-
Neurotoxicity: Monitored via clinical observations and supported by targeted histology of central nervous system tissues.
-
Vector Biodistribution: Quantitative PCR (qPCR) or droplet digital PCR (ddPCR) is used to determine the distribution and clearance of the vector from blood and a comprehensive panel of tissues.
Our scientific team possesses a deep pedigree in navigating these challenges, contributing to a 100% successful IND rate since 2019. While Franklin Biolabs formally launched in 2024, this track record reflects the extensive history of our core principal scientists and study directors in bringing next-generation therapies forward. All studies are conducted within our >100,000 sq ft facility, which includes GxP-compliant environments to support complex, long-term in vivo programs. This integrated approach supports an 18-24 month timeline to get candidates to IND and IMPD filings.
This program-specific preclinical strategy generates the necessary data to support international regulatory submissions, including those to the FDA and the UK’s MHRA, ensuring alignment with global standards for ATMPs.
For more information on our comprehensive capabilities, please see our parent hub page: Cell and Gene Therapy CRO Services.
Featured Video: Franklin BioLab Facility Tour
This site tour showcases Franklin Biolabs’ preclinical and bioanalytical facilities, spanning >100k sq ft of animal housing and specialized laboratory space.
Watch Video Clip
